Eli Lilly’s Lepodisiran Achieves 94% Reduction in Genetic Heart Disease Risk Factor in Phase 2 Trial

The siRNA-based drug shows promise as the first treatment for high lipoprotein(a) levels, with Phase 3 trials underway to assess its impact on cardiovascular events.